Drug
131I-rituximab clinical trials
A product of Rituximab; its studies count on that page too.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Studies by the year they started
3 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 3
Korea Cancer Center Hospital (3)
Studies
Open first, then newest update. How each study uses 131I-rituximab is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)Status unknownPhase 2Korea Cancer Center HospitalNCT01676558Written as 131I-rituximab
- 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell LymphomaStatus unknownPhase 2Korea Cancer Center HospitalNCT01678404Written as 131I-rituximab
- 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell LymphomaStatus unknownPhase 2Korea Cancer Center HospitalNCT01678417Written as 131I-rituximab
Codes
What other systems call 131I-rituximab · ClinicalTrials.gg INT004871
- MeSH (NLM) C507388131I-rituximabOne source NLM
- UNII (FDA) K2I4B6I9L1RITUXIMAB I-131Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C507388 | 131I-rituximab | One source NLM |
| UNII (FDA) | K2I4B6I9L1 | RITUXIMAB I-131 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.